-transparent.png){kind=logo}
1 The free fraction of azapropazone in the plasma of 37 healthy volunteers ranged from 0.0027 to 0.0070 (0.0044 +/- 0.0009, mean +/- s.d.). The principal binding protein was found to be albumin. 2 In 27 patients with various degrees of renal failure the free fraction values of azapropazone were markedly enhanced (0.0260 +/- 0.0239, mean +/- s.d.) and increased more than tenfold in some patients. There was a weak correlation (r = 0.46, P less than 0.05) between the free fraction and the clearance of endogenous creatinine. Such correlation was not found for serum creatinine, serum albumin, serum uric acid and serum urea nitrogen. 3 In 32 patients with chronic liver disease the free fraction values of azapropazone were also markedly higher (0.0210 +/- 0.0242, mean +/- s.d.) than in healthy subjects. There were statistical significant correlation between free fraction values and the prothrombin complex activity in the plasma (r = 0.40, P less than 0.05) and the total bilirubin concentration in the plasma (r = 0.90, P less than 0.001), respectively. Such correlation was not found for serum albumin, serum glutamic oxalacetic transaminase, serum gamma-glutamyl transpeptidase and serum alkaline phosphatase. 4 In patients with kidney and liver disease the free fraction values of azapropazone correlated well with those of the anticoagulant drug phenprocoumon (r = 0.93, P less than 0.001). However, the binding of the latter drug was less impaired. Bilirubin, when added in vitro, displaced both drugs from plasma proteins but this displacing effect was much smaller than the binding changes observed in patients with liver disease. 5 Kidney and liver disease caused a marked impairment of the plasma protein binding of azapropazone. In patients with kidney disease the degree of impairment of azapropazone binding cannot or only poorly (creatinine clearance) be predicted from the biochemical parameters of kidney function whereas in patients with chronic liver disease the total bilirubin concentration in the plasma may serve as an index of the binding defect.
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
April 1975,
European journal of clinical pharmacology,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
December 1982,
Journal of pharmacokinetics and biopharmaceutics,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
November 2002,
Journal of clinical immunology,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
June 2007,
The American journal of the medical sciences,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
January 1984,
Journal of cardiovascular pharmacology,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
January 2015,
Indian journal of nephrology,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
November 2017,
Scandinavian journal of clinical and laboratory investigation,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
April 1987,
Ceskoslovenska farmacie,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
July 2013,
Heart and vessels,
E Jähnchen, and
K J Blanck, and
K H Breuing, and
H J Gilfrich, and
T Meinertz, and
D Trenk
August 1989,
British journal of clinical pharmacology,
